Key result
Emerging metabolic therapies offer promising pathways to restore myocardial energy production in heart failure.
Why the study?
The failing myocardium remains energy depleted despite current heart failure management strategies, prompting development of new metabolic recovery therapies.
Emerging metabolic therapies offer potential new strategies to promote metabolic recovery in the energy-depleted failing myocardium.
Answers are grounded in this paper and cite their sources.
May support metabolic strategies in HF; leaves open their clinical role pending dedicated RCTs.
Heart failure has mortality rates that parallel those of breast cancer. Current management strategies include neurohormonal blockade, rate control measures, natriuretic peptide preservation, implantation of mechanical assist devices, and heart transplantation. Despite these strategies, however, the failing myocardium remains energy depleted. New strategies to promote metabolic recovery are being developed to potentially augment current treatment guidelines. For example, an unexpected finding of our own studies showed that mechanical unloading with assist devices in advanced-stage heart failure restored metabolic flux. Unfortunately, at that point it is too late for myocardial recovery. Traditional metabolic therapies addressing hyperglycemia have had limited long-term outcome benefit. Now, new therapeutic options are emerging based on increased understanding of the molecular mechanisms underlying energy depletion. Metabolic cardiac imaging combined with laboratory diagnostics could guide the design of individual therapeutic strategies. To date, agents that show benefit in select individuals include mimetics that stimulate glucagon-like peptide-1, inhibitors of sodium-glucose cotransporter receptors, drugs that limit fatty acid oxidation, and hormonal therapy in select individuals. This review will summarize mechanisms and investigations related to these metabolic approaches to heart failure.
No takes yet. Share an insight, caveat, or question.
Dale J. Hamilton (2017) conducted a review in Heart failure. Metabolic therapies was evaluated. Emerging metabolic therapies, including GLP-1 mimetics and SGLT-2 inhibitors, offer potential strategies to restore energy production and promote metabolic recovery in the failing myocardium.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: